Compare ROMA & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROMA | ATRA |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.4M | 129.4M |
| IPO Year | 2024 | 2014 |
| Metric | ROMA | ATRA |
|---|---|---|
| Price | $2.29 | $4.55 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 43.0K | ★ 610.3K |
| Earning Date | 12-26-2025 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.97 |
| Revenue | $1,640,101.00 | ★ $151,930,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.31 |
| Revenue Growth | ★ 59.60 | 51.27 |
| 52 Week Low | $0.58 | $4.25 |
| 52 Week High | $4.66 | $19.15 |
| Indicator | ROMA | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 58.04 | 23.81 |
| Support Level | $1.16 | $4.25 |
| Resistance Level | $2.55 | $5.19 |
| Average True Range (ATR) | 0.32 | 1.63 |
| MACD | 0.11 | -1.54 |
| Stochastic Oscillator | 77.70 | 2.07 |
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).